Drug Profile
AIMab 7195
Alternative Names: AIMab-7195; XmAb® 7195Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Xencor
- Developer Aimmune Therapeutics; Xencor
- Class Antiallergics; Antiasthmatics; Food allergy immunotherapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor antagonists; Immunoglobulin E inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Food hypersensitivity
- Discontinued Allergic asthma; Allergic rhinitis; Atopic dermatitis; Conjunctivitis
Most Recent Events
- 05 Oct 2023 AIMab 7195 is still in phase I trial for Food-hypersensitivity in USA (Parenteral) (Xencor pipeline, October 2023)
- 14 Oct 2020 Aimmune Therapeutics has been acquired by Nestle
- 30 Jul 2020 Aimmune plans to submit IND application to the US FDA for Food hypersensitivity (Adjunctive treatment) in first quarter of 2021